Shares in Cellectis shot up this morning after the French biotech revealed a wide-ranging alliance with AstraZeneca which includes $245 million in near-term financial commitments.
According to the partners, the collaboration will focus on using Cellectis’ gene-editing platform and manufacturing capabilities to design cell and gene therapy products, with AZ reserving rights to 25 genetic targets, of which 10 could be explored for development.
